TNFSF10 and non-small cell lung carcinoma: However, the potential of TRAIL as a first-line therapy for advanced NSCLC was greatly dampened when a subsequent randomized phase II study reported little, if at all, improvement in overall patient response rate when TRAIL was included into conventional PCB treatment regimen.42 Despite these setbacks, the potential of death receptor ligation as a chemotherapeutic agent should not be completely disregarded.